Form 4: Director Alan Garber Acquires Vertex Pharmaceuticals DSUs

Director Alan Garber acquired 33.898 deferred stock units of Vertex Pharmaceuticals as part of his board compensation.

Summary

• Director Alan M. Garber acquired 33.898 deferred stock units (DSUs) on April 15, 2026.
• Each DSU represents a right to receive one share of common stock.
• The transaction was valued at $442.50 per unit.
• These units are held directly by the reporting person.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or strategy.

Positives

• Director alignment with shareholder interests through equity-based compensation.

Negatives

• None identified.

Risks

• Value of deferred stock units is subject to market fluctuations in Vertex Pharmaceuticals common stock.

Future Outlook

The deferred stock units will be settled in common stock upon the director's termination of service, a change of control, or in the event of disability or death.

Industry Context

StockSavvy.ai notes that the issuance of deferred stock units to board members is a standard corporate governance practice in the biotechnology sector to ensure long-term alignment between directors and shareholders.

Comparison to Industry Standards

• The use of DSUs for board compensation is consistent with standard practices among large-cap pharmaceutical companies like Amgen, Gilead, and Regeneron.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• The reporting person will hold these units until the occurrence of a triggering event such as retirement or change of control.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, Insider Trading, Director Compensation, Deferred Stock Units